Table 1.

The effects of treatments on the exploration of objects A1 and A2 used during test 1 in the novel object recognition test

Treatment (N)	Object A1 exploration (s)	Object A2 exploration (s)
ITI = 24 h, undisturbed conditions
Vehicle (10)	12.66 ± 1.07	11.70 ± 1.13
ACPC 200 mg/kg (10)	10.84 ± 0.67	11.25 ± 1.20
ACPC 400 mg/kg (10)	11.31 ± 1.38	12.15 ± 1.08
Statistics of two-way mixed-design ANOVA	Treatment: F(2.27) = 0.33; NS Object: F(1.27) = 0.02; NS Treatment × object: F(2.27) = 0.88; NS
ITI = 1 h, ketamine disturbed
Vehicle (10)	8.37 ± 0.78	9.43 ± 0.62
VEH + KET 20 mg/kg (9)	10.38 ± 0.95	12.09 ± 1.20
ACPC 400 + KET 20 mg/kg (10)	9.15 ± 0.68	10.58 ± 1.06
Statistics of two-way mixed-design ANOVA	Treatment: F(2.26) = 2.50; NS Object: F(1.26) = 5.44; P < 0.05 Treatment × object: F(2.26) = 0.90; NS
ITI = 1 h, PCP disturbed
Vehicle (8)	10.83 ± 0.73	9.75 ± 0.59
VEH + PCP 5 mg/kg (9)	9.23 ± 1.13	9.61 ± 0.82
ACPC 200 + PCP 5 mg/kg (10)	8.85 ± 1.27	8.73 ± 1.09
ACPC 400 + PCP 5 mg/kg (10)	9.89 ± 1.46	10.01 ± 0.94
Statistics of two-way mixed-design ANOVA	Treatment: F(3.33) = 0.50; NS Object: F(1.33) = 0.08; NS Treatment × object: F(3.33) = 0.26; NS
ITI = 1 h, PCP disturbed
Vehicle (9)	8.76 ± 1.08	8.54 ± 0.52
VEH + PCP 5 mg/kg (9)	7.31 ± 1.00	7.60 ± 1.13
Clozapine 1 + PCP 5 mg/kg (11)	6.95 ± 1.18	9.08 ± 0.86
Statistics of two-way mixed-design ANOVA	Treatment: F(2.26) = 0.53; NS Object: F(1.26) = 1.03; NS Treatment × object: F(2.26) = 1.05; NS